Russell Madison

Russell Madison

UNVERIFIED PROFILE

Are you Russell Madison?   Register this Author

Register author
Russell Madison

Russell Madison

Publications by authors named "Russell Madison"

Are you Russell Madison?   Register this Author

24Publications

412Reads

43Profile Views

TKI-resistant -rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations.

Lung Cancer (Auckl) 2019 15;10:81-86. Epub 2019 Aug 15.

Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S212406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699522PMC
August 2019

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

J Clin Oncol 2018 Oct 20:JCO1801148. Epub 2018 Oct 20.

Andrea Necchi, Andrea Anichini, Daniele Raggi, Simona Massa, Maurizio Colecchia, Patrizia Giannatempo, Roberta Mortarini, Elena Farè, Francesco Monopoli, Antonella Messina, Roberto Salvioni, and Luigi Mariani, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori; Alberto Briganti, Roberta Lucianò, Marco Bianchi, Renzo Colombo, Andrea Gallina, Andrea Salonia, and Francesco Montorsi, Vita Salute San Raffaele University and Urological Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Hospital, Milan, Italy; Siraj M. Ali, Russell Madison, Jeffrey S. Ross, and Jon H. Chung, Foundation Medicine, Cambridge, MA; and Jeffrey S. Ross, Upstate Medical University, Syracuse, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01148
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01148DOI Listing
October 2018

Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.

J Thorac Oncol 2018 08;13(8):e148-e150

Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Floria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.028DOI Listing
August 2018

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Eur Urol 2018 07;74(1):124-128

Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183025
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.03.032DOI Listing
July 2018

WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.

J Thorac Oncol 2018 07;13(7):e122-e123

Foundation Medical, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.003DOI Listing
July 2018

Increased expression of melanoma stem cell marker CD271 in metastatic melanoma to the brain.

Int J Clin Exp Pathol 2014 1;7(12):8947-51. Epub 2014 Dec 1.

Department of Pathology, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313973PMC
October 2015

Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers.

Int J Clin Exp Pathol 2013 15;6(8):1658-64. Epub 2013 Jul 15.

Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma city, Oklahoma 73104, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726983PMC
March 2014